News coverage about NewLink Genetics (NASDAQ:NLNK) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NewLink Genetics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.1757470331968 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of NewLink Genetics (NASDAQ NLNK) opened at $8.58 on Friday. NewLink Genetics has a 12-month low of $5.90 and a 12-month high of $25.17. The company has a market capitalization of $320.35, a P/E ratio of -3.52 and a beta of 1.10.
NewLink Genetics (NASDAQ:NLNK) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%. analysts expect that NewLink Genetics will post -2.65 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/markets/newlink-genetics-nlnk-receives-daily-media-sentiment-score-of-0-17/1872700.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.